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Diabetes and all-cause mortality, a 
18-year follow-up study
Rezvan Salehidoost1, Asieh Mansouri2, Massoud Amini1*, Sima Aminorroaya Yamini3 & 
Ashraf Aminorroaya1*
This study compared mortality rates and decline in life expectancy of Iranian patients with type 2 
diabetes (T2DM) with the general population. A retrospective study of 2451 patients with T2DM was 
conducted in the Isfahan Endocrine and Metabolism Research Center, Iran, between 1992 and 2010. 
The mean (SD) of diabetes duration and median (Q1,Q3) of follow-up period were 15.5(8.0) and 8(5, 10) 
years. The main outcome was all-cause mortality. 732(29.87%) of patients died during the follow-up. 
Overall mortality rates (95%CI) per 1000 person-years in men and women were 56.3(52.0–62.1) and 
27.3(24.5–30.4), respectively. The relative risks (95%CI) of all-cause mortality in males vs. females with 
T2DM aged 45–49, 50–54, 55–59, 60–64, 65–69, 70–74 were [3.02(1.49–6.11) vs. 2.09(0.96–4.57)], 
[4.05(2.73–6.01) vs. 2.29(1.52–3.45)], [4.13(3.26–5.24) vs. 1.70(1.23–2.35)], [2.42(1.90–3.07) vs. 
1.82(1.46–2.27)], [2.36(2.02–2.76) vs. 1.49(1.25–1.78)] and [1.71(1.50–1.95) vs. 1.04(0.88–1.23)] times 
more than the general population, respectively. Men and women living with diabetes lost an average 
of 13.2(6.3) and 13.9(6.0) life-years from the year of diagnosis, respectively (p = 0.101). The estimated 
life-years lost were greater in younger patients and a gradual decline was observed with increasing the 
age at diagnosis. In conclusion, Iranians with diabetes had higher risk of death and lower life expectancy 
compared to the general population.
Type 2 diabetes mellitus (T2DM) is one of the most common health issues. There is a growing prevalence of 
T2DM, worldwide. In general, diabetes and its complications are leading causes of mortality in most countries1–4. 
Approximately 5.0 million deaths in 2015 was attributed to people, 20–79 years of age with diabetes, equivalent to 
one death in every six seconds1. The global all-cause mortality rate attributed to diabetes is 14.5% among people 
within this range of ages. This is higher than the combined number of deaths occurred by the infectious diseases1.
Studies have shown that the age-adjusted all-cause mortality in patients with diabetes is higher than the gen-
eral population or people without diabetes2,5–10. Therisk of mortality tends to increase with diabetes duration and 
decreases with increasing age at which diabetes is diagnosed2,6,7,9,10. Lower life expectancy is reported for people 
with diabetes compared to people without diabetes2,7,8. However, majority of these studies were performed in 
Western populations2,5–8,10 and to our best of knowledge, there is no published data available for the excess risk of 
death and potential years of life lost in Iranian patients with T2DM.
The aim of the present study was to evaluate the mortality rates among people with diabetes compared to the 
general population of Iran according to age and sex. We also estimated the effect of diabetes on the expected life 
years by using clinical data registry records for patients with diabetes at the Isfahan Endocrine and Metabolism 
Research Center, Iran.
Material and Methods
This retrospective database study was conducted in Isfahan, a large urban area located in the centre of Iran, with 
a population more than four and a half million (4,879,312 in 2011 (2,476,021 men and 2,403,291 women))11. 
The database of the Isfahan Endocrine and Metabolism Research Center was used to extract characteristic infor-
mation of people with T2DM, registered in this center. Clinical data are collected for all patients by continuous 
enrollment at the first attendance and at follow up visits, which were performed with interval of 2 to 12 months. 
The demographic characteristics, medications and family medical history were recorded. The height, weight 
and blood pressure were measured and a general examination was performed at every visit. Fasting plasma glu-
cose (FPG), HbA1c, triglyceride, cholesterol and other routine laboratory test were conducted for patients with 
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diabetes. Patients’ data recording were continued from the baseline examination until they died or stopped the 
follow-ups. All patients were given informed consent for participation in the examination and registration.
Between year 1992 and 2010, a total number of 11748 patients with T2DM were registered in the system. 
However, this study only included 2502 of patients with T2DM who had follow-up visits and their survival sta-
tus was known in 2010. Patients with missing data for sex (n = 2), age (n = 4), the age of death (n = 4) and the 
duration of diabetes (n = 16) or those patients who were diagnosed with diabetes at ages younger than 20 (most 
probably type 1 diabetes) (n = 25) were excluded from the analyses. Finally, a total number of 2451 (993 (40.51%) 
men and 1458 (59.49%) women) with T2DM were included in the analysis (Fig. 1). Diabetes was defined as fast-
ing plasma glucose ≥ 126 mg/dl or 2-hour plasma glucose ≥ 200 mg/dl after taking a 75-g oral glucose tolerance 
test using American Diabetes Association criteria12, or current treatment with oral antidiabetes drugs or insulin.
Our main outcome of interest was all-cause mortality. Death event was recorded annually. The baseline vari-
ables were obtained at the time of entry into the registry. Body mass index (BMI) was calculated as weight in kg 
divided by squared height in meters. Height and weight of patients were measured wearing light clothes and no 
footwear in the standing position while the shoulders were in the normal state using Seca stadiometer. The weight 
values were rounded to the nearest 0.1 kg. The baseline weight and height of patients were used to calculate their 
BMI. Resting systolic (SBP) and diastolic blood pressure (DBP)were measured after the patient seated for 5 min-
utes by using a calibrated mercury sphygmomanometer (Rester, Germany) with standard method recommended 
by the American Heart Association13. Blood pressure was measured twice on the same arm and the same patient 
position if blood pressure was high, and the mean value was recorded. Fasting plasma glucose was measured 
using the glucose oxidase method. Total cholesterol and HDL-cholesterol were measured by CHOD-PAP and 
triglyceride was determined by GPO-PAP methods. LDL-cholesterol was calculated using friedewald formula 
when total triglyceride was less than 400 mg/dL and non-HDL-cholesterol by subtracting HDL-cholesterol from 
the total cholesterol value.
Duration of diabetes was calculated by adding the duration of follow up for each case to the duration of dia-
betes at the baseline. Duration of diabetes at the baseline was estimated either from the date of the first abnormal 
laboratory report for diabetes or the date of the first diabetes-related treatment, whichever was earlier. Follow up 
duration was calculated from the date of examination at the baseline to the time of death, otherwise up to 2010.
Life table is a key tool and a convenient method to compare the mortality and analyse death rates at various ages. 
Under the null hypothesis that patients with diabetes had a higher mortality risk than the general population, we 
Figure 1. Selection process of participants.
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used the national life tables for Iran in 200414 to compare mortality rates of people with type 2 diabetes with the 
general population according to sex and age.
Laboratory analyses were carried out at the Isfahan Endocrine and Metabolism Research Center. The study 
was approved by the Medical Ethics Committee of the Isfahan University of Medical Sciences.
Statistical analysis. The statistical analysis of the data was conducted with the STATA software version 11.0. 
Comparison of the baseline characteristics by participation status were performed by Student’s t-test. We estimated 
total, sex- and age-specific all-cause mortality rates (per 1000 person-years). In addition, for both males and females, 
we estimated mortality rates for five different diabetes duration (0–4, 5–9, 10–14, 15–19, and > = 20 years) for patients 
of all age groups and separately for patients aged < = 60 years and those aged >60 years. These rates were calculated as 
the number of subjects who died in each group, divided by the person-years of follow up. We calculated un-adjusted 
age-sex specific relative risk by dividing aforementioned rates per correspondent mortality rates in the general popu-
lation. Life-years lost were estimated for each deceased person using age-group life expectancies reported for Iranian 
general population. We subtracted the age of death for each deceased person from his/her expected years of life. The 
national life tables for Iran in 2004 were used to estimate the relative risk and life-years lost14.
Ethical approval. All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards. The study was approved by the ethics 
Committee of the Isfahan University of Medical Sciences.
Informed consent. Informed consent was obtained from all patients for participation and registration.
Results
In total, 2451 patients with T2DM (993 (40.51%) men and 1458 (59.49%) women) were studied. Mean (SD) of 
diabetes duration was 7.8 (3.9) and median (Q1, Q3) of follow-up was 8 (5, 10) years. 732 (29.87%) of patients 
(406 (40.89%) men and 326 (22.36%) women (p < 0.001)) died during the follow-up.
Baseline characteristics by survival status are presented in Table 1. The values of some variables, including 
diabetes duration, SBP, DBP, FPG, LDL-cholesterol, HbA1c and smoking status, were higher in dead than live 
people. The proportion of patients treated with insulin, oral agents, diet and combination of insulin and oral 
agents were 10.6%, 64.5%, 22.4% and 2.4%, respectively. Dead people were more likely to be treated with insulin 
(20.3% vs. 6.9%), and less likely to receive oral agents (57.7% vs. 67.2%), dietary treatment (20.0% vs. 23.4%) and 
to be treated with combination of insulin and oral agents (2.1% vs. 2.6%) than live people.
The baseline characteristics by participation status can be found as Supplementary Table S1. Some varia-
bles (SBP, DBP, FPG, triglyceride and Hb1Ac) showed statistically significant differences between included and 
excluded patients, however, these differences were trivial and clinically negligible (Table S1).
Variables
Total (n = 2451) Alive (n = 1719) Dead (n = 732)
Mean or Number 
(SD or %)
Mean or Number 
(SD or %)
Mean or Number 
(SD or %)
Age (year) (n = 2451) 53.3 (10.1) 50.1 (8.8) 60.8 (8.9)
Age group(year)
≤ 60 1208 (49.3) 1047 (86.7) 161 (13.3)
> 60 1243 (50.7) 672 (54.1) 571 (45.9)
Sex
Male 933 (40.5) 587 (34.2) 406 (55.5)
Female 1458 (59.5) 1132 (65.9) 326 (44.5)
Diabetes duration (years) (n = 2451) 15.5 (8.0) 12.8 (6.5) 21.7 (7.8)
BMI (kg/m2) (n = 2369) 27.7 (4.5) 28.3 (4.4) 26.2 (4.4)
SBP (mmHg) (n = 2373) 127.1 (20.2) 123.8 (17.6) 135.6 (23.7)
DBP (mmHg) (n = 2372) 78.4 (12.3) 77.1 (11.9) 81.7 (12.6)
FPG (mg/dl) (n = 2408) 186.9 (71.6) 178.3 (66.9) 208.2 (78.2)
HDL-C (mg/dl) (n = 1964) 44.5 (11.4) 44.5 (11.3) 44.0 (12.5)
LDL-C (mg/dl) (n = 1802) 130.3 (42.4) 128.2 (40.7) 146.7 (50.8)
Non-HDL-C (mg/dl) (n = 1948) 174.6 (49.6) 172.5 (48.0) 190.0 (58.2)
HbA1c (%) (n = 1779) 8.4 (2.1) 7.5 (1.7) 10.1 (2.3)
Smoking (Yes) (n = 1934) 235 (12.2) 107 (8.5) 128 (19.1)
Treatment status
Insulin 255 (10.6) 118 (6.9) 137 (20.3)
Oral agent 1545 (64.5) 1155 (67.2) 390 (57.7)
Diet 537 (22.4) 402 (23.4) 135 (20.0)
Insulin&oral agents 58 (2.4) 44 (2.6) 14 (2.1)
Table 1. Baseline characteristics of patients with T2DM by survival status. aP value based on Student’s T-test 
between total included participants and excluded participants, BMI: body mass index; SBP: systolic blood 
pressure; DBP: diastolic blood pressure; FPG: fasting plasma glucose, C: Cholesterol, TG: triglyceride, HDL: 
high density lipoprotein, LDL: low density lipoprotein.
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The rate of mortality was increased with diabetes duration based on sexes and in 5-year intervals (Table 2). The 
mortality rates (95%CI) in all participants were 0, 6.6(4.3–10.3), 18.3(15.1–22.2), 43.8(38.3–50.2) and 74.3(67.3–
82.0) per 1000 person-years for diabetes duration <5, 5–9, 10–14, 15–19 and ≥20 years, respectively. The mor-
tality rates in males were higher than female patients in all categories. Overall mortality rates (95%CI) per 1000 
person-years in men and women were 56.3(52.0–62.1) and 27.3(24.5–30.4), respectively. The patients were classi-
fied into two categories (age 60 years or less and more than 60 years) in order to control the age effect in assessing 
association between all-cause mortality rate and diabetes duration. The same results were obtained for both age 
categories (Table 2). Overall mortality rates in patients aged 60 years or less was.
All-cause mortality rates by age at the end of study in women and men are presented in Table 3. The results 
showed that the mortality rate among patients with diabetes was higher than the general population in all age 
groups except for the age group of ≥75 years old. The relative risks (95%CI) of all-cause mortality in males vs. 
females with T2DM aged 45–49, 50–54, 55–59, 60–64, 65–69, 70–74 were [3.02(1.49–6.11) vs. 2.09(0.96–4.57)], 
[4.05(2.73–6.01) vs. 2.29(1.52–3.45)], [4.13(3.26–5.24) vs. 1.70(1.23–2.35)], [2.42(1.90–3.07) vs. 1.82(1.46–2.27)], 
[2.36(2.02–2.76) vs. 1.49(1.25–1.78)] and [1.71(1.50–1.95) vs. 1.04(0.88–1.23)] times more than the general pop-
ulation, respectively.
Mean (SD) years of life lost by age at diagnosis and sex are shown in Table 4. The youngest age group (<40 
years old) had the highest years of life lost (20.2(7.1) for men and 21.8(5.4) for women), however with increasing 
age, it gradually declined (5.4(1.5) for men and 5.1(1.5) for women, aged 70–75 years old). We found that diabetes 
cuts life expectancy by 3.1(0.0) to 21.8(5.4) years according to age and sex. Men and women with diabetes lost 
an average of 13.2(6.3) and 13.9(6.0) life-years from the year of diagnosis, respectively (p = 0.101) (Table 4). The 
total years lost by age at diagnosis and sex are shown in Fig. 2. Considering we summed number of years lost for 
each age- and sex- specific group, values of y-axis have been increased to 2000 to cover all age- and sex- specific 
years lost.
Discussion
In this observational study, 2451 patients with T2DM were followed for 18 years. We found, first, the patients 
with diabetes, aged 40–75 years old, according to sex and age, were at 1.04–4.13 times higher risk of mortality 
compared to the general population. Second, the excess mortality decreased with increasing age in both sexes 
compared to the general population. Third, the rate of mortality increased with diabetes duration in both sexes. 
Finally, men and women lost an average of 13.2(6.3) and 13.9(6.0) years from the age of diagnosis with diabetes, 
respectively. There is a gradual decline in years of life lost with increasing age of diabetes diagnosis.
The excess risk of mortality among people with diabetes has shown in previous studies2,6,15. These studies have 
also reported that relative risk of mortality tends to decline with increasing age. A Swedish national study showed 
that mortality rate increased between 100% to 200% among patients with T2DM, younger than 55 years old, com-
pared to the general population; whereas the excess risk of death ranged from 30% to 40% among patients aged 65 
to 74 years old2. A cohort study in Mexican adults reported that rate ratios for all-cause mortality in people with 
diabetes was 5.4 for 35–59 years old and 3.1 for60–74 years old patients15. Danish population with diabetes was 
Variable
Both sexes Males Females
Number Deaths MR (95% CI) Number Deaths MR (95% CI) Number Deaths MR (95% CI)
All age groups
Diabetes duration
0–4 y 118 0 0.0 46 0 0.0 72 0 0.0
5–9 y 493 20 6.6 (4.3–10.3) 180 9 8.0 (4.2–15.4) 313 11 5.8 (3.2–10.4)
10–14 y 679 105 18.3 (15.1–22.2) 260 63 30.7 (24.0–39.3) 419 42 11.4 (8.4–15.5)
15–19 y 525 211 43.8 (38.3–50.2) 203 111 65.8 (54.6–79.2) 322 100 32.0 (26.3–38.9)
≥20 y 636 396 74.3 (67.3–82.0) 304 223 99.0 (86.8–112.9) 332 173 56.2 (48.4–65.2)
Total 2451 732 38.2 (35.5–41.1) 993 406 56.3 (52.0–62.1) 1458 326 27.3 (24.5–30.4)
Age group ≤60 years
Diabetes duration
0–4 y 112 0 0.0 44 0 0.0 68 0 0.0
5–9 y 366 4 1.9 (0.7–5.0) 130 2 2.6 (0.7–10.4) 236 2 1.5 (0.4–5.8)
10–14 y 373 24 7.7 (5.2–11.5) 120 16 17.7 (10.8–28.9) 253 8 3.6 (1.8–7.3)
15–19 y 215 51 25.2 (19.2–33.2) 69 28 47.1 (32.5–68.2) 146 23 16.1 (10.7–24.2)
≥20 y 142 82 76.0 (61.2–94.4) 61 44 113.1 (84.2–142.0) 81 38 55.1 (40.1–75.7)
Total 1208 161 18.8 (16.1–21.9) 424 90 32.8 (26.6–40.3) 784 71 12.2 (9.6–15.4)
Age group >60 years
Diabetes duration
0–4 y 6 0 0.0 2 0 0.0 4 0 0.0
5–9 y 127 16 18.0 (11.0–29.3) 50 7 19.7 (9.4–41.4) 77 9 16.8 (8.7–32.3)
10–14 y 306 81 30.9 (24.8–38.4) 140 47 40.9 (30.7–54.4) 166 34 23.1 (16.5–32.3)
15–19 y 310 160 57.3 (49.1–66.9) 134 83 75.9 (61.2–94.2) 176 77 45.3 (36.2–56.7)
≥20 y 394 314 73.8 (66.1–82.5) 243 179 96.1 (83.0–111.2) 251 135 56.5 (47.7–66.9)
Total 1243 571 54.0 (49.8–58.6) 569 316 70.8 (63.4–79.0) 674 255 41.7 (36.9–47.2)
Table 2. Sex- and age-specific all-cause mortality rates by diabetes duration in patients with T2DM. MR: 
mortality rate; aRates were calculated per 1000 PY (person-years).
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at 1.5–2.5 times higher risk of mortality compared to the general population6. This risk decreased with age and at 
ages of more than 80 years, the mortality rate difference between the general population and patients with diabe-
tes was small6. This decline of mortality rate with age might be caused by more sever effects of diabetes in younger 
people16,17. However, ageing also increases the risk of other life-threatening diseases in the general population18 
whichmight increase the mortality rate in the older general population.
In the current study, the rate of mortality increased with diabetes duration. Our finding is consistent with 
previous studies19–21; In the Verona Diabetes Study (VDS), death rates rose in both sexes with increasing duration 
of diabetes19. In a cohort study, a10-yearlonger duration of diabetes was correlated with a 1.2–1.3 times increased 
risk of all-cause mortality in Australian patients with diabetes20. Another study in Mexico reported significantly 
increased rates of death from diabetes with duration of diabetes21. Longer duration of diabetes (equivalent to diag-
nosis of diabetes at younger age) increases the exposure to hyperglycaemia, which is correlated to an increased 
risk of complications16,17,22. Moreover, previousstudies17,23 have shown that early onset of T2DM is associated with 
more adverse cardiovascular risk profile. Prolong exposure to hyperglycaemia combined with the presence of 
multiple cardiovascular risk factors increases morbidity and mortality in patients with long duration of diabetes22.
Our study showed that the youngest age group (<40 years old) of patients with diabetes had the largest years 
of life lost (20.2 for men and 21.8 for women) and years of life lost was gradually declined with age (5.4 for men 
and 5.1 for women, aged 70–75 years old). We found that diabetes cut the life expectancy by 3.1 to 21.8 years 
according to age and sex with an average of 13.2 and 13.9 years in men and women, respectively. Different num-
bers of life-years lost have been reported for patients with diabetes by studies at various geographical area, racial 
background, sex and healthcare systems7–9. 6.10 years of life years lost is reported for Korean patients with diabe-
tes in a cohort study, this number was declined with age9. Another study used NHIS data of the USA and found 
diabetes cut life expectancy by 3.30 to 18.74 years depending on age, sex, race, and BMI. Life years lost was also 
reported to decline with age7. A recent cohort study in England showed at age 40, white men and women with 
diabetes lost 5 and 6 years of life respectively, compared to those without diabetes8. The years of life lost in our 
study, were higher than previous reports. The early deaths might be the combination of several factors: the rapid 
changes in the lifestyle that led to reduced levels of physical activities; overconsumption of energy-dense food that 
results in obesity and young-onset diabetes24; late diagnoses of diabetes and the health systems that are not ready 
to provide optimal management to the increasing numbers of people with diabetes.
Age at the end 
of the study Number Deaths MRa
(95% Confidence 
Interval) PMRb
Relative Risk (95% 
Confidence Interval)c
Women
30–34 1 0 0.0 — 1.3 —
35–39 16 0 0.0 — 1.5 —
40–44 58 0 0.0 — 2.1 —
45–49 128 6 6.7 (3.0–14.9) 3.2 2.09 (0.96–4.57)
50–54 251 21 11.7 (7.6–18.0) 5.1 2.29 (1.52–3.45)
55–59 287 33 13.6 (9.7–19.2) 8.0 1.70 (1.23–2.35)
60–64 243 60 27.5 (21.3–35.4) 15.1 1.82 (1.46–2.27)
65–69 213 77 40.6 (32.4–50.7) 27.2 1.49 (1.25–1.78)
70–74 146 72 51.9 (41.2–65.4) 49.7 1.04 (0.88–1.23)
75–79 77 39 58.6 (42.8–80.3) 88.5 0.66 (0.53–0.82)
80–84 30 14 52.6 (31.2–88.9) 174.7 0.30 (0.20–0.44)
≥ 85 7 4 59.7 (22.4–159.1) 376.9 0.16 (0.08–0.30)
Men
30–34 0 0 0.0 — 2.7 —
35–39 9 1 25.6 (3.6–182.0) 2.9 8.83 (1.39–56.05)
40–44 28 1 6.4 (0.9–46.1) 3.7 1.73 (0.25–11.86)
45–49 73 7 15.1 (7.2–31.7) 5.0 3.02 (1.49–6.11)
50–54 105 20 30.4 (19.6–47.2) 7.5 4.05 (2.73–6.01)
55–59 169 49 43.4 (32.8–57.4) 10.5 4.13 (3.26–5.24)
60–64 135 45 42.9 (32.0–57.5) 17.7 2.42 (1.90–3.07)
65–69 143 75 68.7 (54.8–86.1) 29.1 2.36 (2.02–2.76)
70–74 149 89 80.7 (65.6–99.3) 47.2 1.71 (1.50–1.95)
75–79 122 79 80.3 (64.4–100.1) 79.1 1.02 (0.89–1.16)
80–84 46 31 72.4 (50.9–103.0) 151.1 0.48 (0.39–0.59)
≥ 85 14 9 81.1 (42.2–155.8) 318.1 0.25 (0.17–0.37)
Table 3. All-cause mortality rates in Iranian patients with T2DM, compared to 2004 national life table. 
aMortality rate calculated as the number of subjects who died at each group, divided by the person-years (PY) of 
follow up. Rates were calculated per 1000 PY. bPopulation Mortality Rates, adopted from 2004 national life table 
for Iran, reported by Khosravi et al.14. cIt was calculated by this formula: ± +− −RR zLn( ) n x xn
n x x
n
( ) / ( ) /1 1 1
1
2 2 2
2
. 
Then we took the antilog (exp) of the lower and upper limits.
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We have found a significantly higher mortality rate in men compared to women with diabetes. This is also 
occurred in the Iranian general population aged less than 70 years old14. This study reported all-cause mortality, 
not diabetes related mortality, and therefore, the higher rates of mortality in men, similar to the general popula-
tion, might be due to other causes such as car or workplace accidents.
The present study has several strengths and limitations. This is the first retrospective database study, focusing 
on the mortality rate and the effect of diabetes on the expected life years among Iranian people with long-term 
follow-up (18 years). The limitations of the current study include: (i) referral bias in the clinic-based studies is 
likely to produce higher mortality rates than in the community-based studies; (ii) we have analysed the data for 
patients with T2DM with follow-up visits and clear outcome in 2010. Those patients with irregular visits and 
unclear outcome were excluded which may cause a selection bias. However, we compared the baseline charac-
teristics between the included and excluded groups, which indicated clinically trivial differences and therefore, 
we expect this bias to be negligible; (iii) use of local population without diabetes as the comparison group can 
minimize the bias in the estimation of mortality ratios. However, the data for mortality rates in the local popula-
tion without diabetes was unavailable; (iv) the data for the mortality caused by cardiovascular disease or cancer 
and information about some medications such as anti-hypertensive and lipid-lowering drugs at the baseline were 
unavailable.
In conclusion, our study showed people with diabetes were at higher risk of death and lower life expectancy 
compared to the general population. The young people with diabetes lost more years of life compared to people 
who diagnosed with diabetes at the older ages. Therefore, more healthcare attention should be paid to these 
patients to improve their life expectancy.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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Age at diagnosis
Male Life-years losta Female Life-years losta Total Life-years losta
Number Mean (SD) Number Mean (SD) Number Mean (SD)
<40 59 20.2 (7.1) 35 21.8 (5.4) 94 20.8 (6.5)
40–44 45 16.5 (6.6) 59 17.8 (5.2) 104 17.2 (5.8)
45–49 66 15.5 (5.2) 58 15.3 (5.1) 124 15.4 (5.1)
50–54 70 12.2(4.5) 56 12.9 (4.1) 126 12.5 (4.3)
55–59 76 11.1 (3.2) 50 11.3 (3.0) 126 11.2 (3.1)
60–64 44 8.7 (2.6) 37 9.4 (2.8) 81 9.0 (2.7)
65–69 36 7.2 (2.1) 22 7.2 (2.0) 58 7.2 (2.1)
70–74 8 5.4 (1.5) 9 5.1 (1.5) 17 5.3 (1.4)
≥ 75 2 3.1 (0.0) 0 — 2 3.1 (0.0)
Total 406 13.2 (6.3) 326 13.9 (6.0) 732 13.5 (6.2)
Table 4. Mean life-years lost for Iranian patients with T2DM, compared to the general population using 2004 
national life table. aLife-years lost were estimated for each deceased person by subtracting the age of death for 
each deceased person from his/her expected years of life.
Figure 2. Total life-years lost for people with T2DM by age at diagnosis.
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